Literature DB >> 12931219

BRAF gene is not mutated in plasma cell leukemia and multiple myeloma.

L Bonello, C Voena, M Ladetto, M Boccadoro, G Palestro, G Inghirami, R Chiarle.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12931219     DOI： 10.1038/sj.leu.2403116

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authors:  Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter Burger; Mathew J Rumizen; Klaus Podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Br J Haematol       Date:  2010-03-12       Impact factor: 6.998

2.  Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias.

Authors:  Eleftheria Hatzimichael; Samuel Murray; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-05-05

Review 3.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

Review 4.  Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network.

Authors:  Rimda Wanchoo; Kenar D Jhaveri; Gilbert Deray; Vincent Launay-Vacher
Journal:  Clin Kidney J       Date:  2016-01-18

Review 5.  Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples.

Authors:  Esther Diana Rossi; Maurizio Martini; Tommaso Bizzarro; Fernando Schmitt; Adhemar Longatto-Filho; Luigi Maria Larocca
Journal:  Oncotarget       Date:  2017-01-10

Review 6.  Comparative Aspects of BRAF Mutations in Canine Cancers.

Authors:  Hiroyuki Mochizuki; Matthew Breen
Journal:  Vet Sci       Date:  2015-08-24

7.  MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.

Authors:  C Chang-Yew Leow; S Gerondakis; A Spencer
Journal:  Blood Cancer J       Date:  2013-03-22       Impact factor: 11.037

8.  Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease.

Authors:  L Lodé; P Moreau; A Ménard; C Godon; C Touzeau; M Amiot; S Le Gouill; M C Béné; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-11-22       Impact factor: 11.037
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.